Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
KURA
KURA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KURA News
Kura Oncology Grants Stock Options to New Employees
Feb 06 2026
Newsfilter
Kura Oncology Reports $2.1M KOMZIFTI Revenue in 2025 Financial Results
Jan 12 2026
NASDAQ.COM
Kura Oncology Launches KOMZIFTI, First Once-Daily Oral Menin Inhibitor with $2.1M Initial Revenue
Jan 11 2026
Globenewswire
Kura Oncology Launches KOMZIFTI, First Once-Daily Oral Menin Inhibitor with $2.1M Initial Revenue
Jan 11 2026
Yahoo Finance
Kura Oncology Gains Ground After Jim Cramer's Remarks
Dec 22 2025
SeekingAlpha
After-Hours Gains on Friday: Biotech and Genomics Stocks Demonstrate Resilience
Dec 22 2025
NASDAQ.COM
Kura Oncology Reports 86% CR Rate for KOMZIFTI in AML Treatment
Dec 08 2025
Newsfilter
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
Dec 04 2025
Newsfilter
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
Dec 04 2025
PRnewswire
Kura Receives $135 Million Milestone Payment Following First U.S. Commercial Sale of KOMZIFTI
Dec 03 2025
NASDAQ.COM
Kura Oncology Completes First U.S. Sale of KOMZIFTI, Triggering $135 Million Payment
Dec 02 2025
Globenewswire
Kura and Kyowa Kirin Launch KOMZIFTI™ for AML Treatment
Nov 25 2025
Newsfilter
KOMZIFTI™ (ziftomenib) Included in NCCN Guidelines for Acute Myeloid Leukemia (AML)
Nov 25 2025
Yahoo Finance
Noteworthy KURA Put and Call Options Set for July 2026
Nov 25 2025
NASDAQ.COM
Upcoming FDA Drug Approvals: A Look at the FDA Calendar
Nov 20 2025
TipRanks
Kura Celebrates Major Success with FDA Approval of New Leukemia Medication
Nov 14 2025
Benzinga
Show More News
